Loading…
Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study
Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either super...
Saved in:
Published in: | The American heart journal 2011-12, Vol.162 (6), p.1003-1010 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53 |
---|---|
cites | cdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53 |
container_end_page | 1010 |
container_issue | 6 |
container_start_page | 1003 |
container_title | The American heart journal |
container_volume | 162 |
creator | Whellan, David J., MD, MHS Nigam, Anil, MD Arnold, Malcolm, MD Starr, Aijing Z., MS Hill, James, MD, MS Fletcher, Gerald, MD Ellis, Stephen J., PhD Cooper, Lawton, MD Onwuanyi, Anekwe, MD Chandler, Bleakley, MD Keteyian, Steven J., PhD Ewald, Greg, MD Kao, Andrew, MD Gheorghiade, Mihai, MD |
description | Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms. |
doi_str_mv | 10.1016/j.ahj.2011.09.017 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_908739669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002870311007022</els_id><sourcerecordid>908739669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIREPhAdggSwjBJsE_ydgjJKQStbRSpS4Ia8uxrxOHiR1sT8TseAiei4fgSfCQlEpddGVZ_s65Pz5V9ZLgCcGkfr-ZqPVmQjEhE9xMMOGPqhHBDR_XfDp9XI0wxnQsOGYn1bOUNuVaU1E_rU4oJYxjzkbV70_gwbqMgkXwA6J2CVBeQ1S7HtkQUepTDq3TaA0qZmSVa7sIyHkUoVXZBY9yQKbIVFEm2EN0uUfKGwTltQ2r_s_PX9Z54_wqIRvDdvBHl__sLo52A36G5sHnGNoWDFpEp1p05feQsluVOn6FbrqswxbS0Ov5ba-LqJwfXlPuTP-8emJVm-DF8Tytvl6cL-aX4-ubz1fzs-uxrjHPY2saYQXDRtuGGWGYXtqpJYwsl5wLwmdKzAQwRY2iVlDGLK2N4LW2S1ETmLHT6u3BdxfD9670KLcuaWhb5SF0STZYcNbUdVPIdw-SZMamgoipGExf30M3oYu-zFEoQmssGjoYkgOlY0gpgpW76LYq9pJgOcRCbmSJhRxiIXEjSyyK5tXRuVtuwfxX3OagAG-OgEpatTYqX7Z7x80YnhFBCvfhwEFZ7t5BlEk78BqMi6CzNME92MbHe2rdls8rBb9BD-luWpmoxPLLkN8hvoRgzDGl7C-5u-6t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1512608929</pqid></control><display><type>article</type><title>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</title><source>Elsevier</source><creator>Whellan, David J., MD, MHS ; Nigam, Anil, MD ; Arnold, Malcolm, MD ; Starr, Aijing Z., MS ; Hill, James, MD, MS ; Fletcher, Gerald, MD ; Ellis, Stephen J., PhD ; Cooper, Lawton, MD ; Onwuanyi, Anekwe, MD ; Chandler, Bleakley, MD ; Keteyian, Steven J., PhD ; Ewald, Greg, MD ; Kao, Andrew, MD ; Gheorghiade, Mihai, MD</creator><creatorcontrib>Whellan, David J., MD, MHS ; Nigam, Anil, MD ; Arnold, Malcolm, MD ; Starr, Aijing Z., MS ; Hill, James, MD, MS ; Fletcher, Gerald, MD ; Ellis, Stephen J., PhD ; Cooper, Lawton, MD ; Onwuanyi, Anekwe, MD ; Chandler, Bleakley, MD ; Keteyian, Steven J., PhD ; Ewald, Greg, MD ; Kao, Andrew, MD ; Gheorghiade, Mihai, MD</creatorcontrib><description>Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2011.09.017</identifier><identifier>PMID: 22137073</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyopathy ; Cardiovascular ; Cardiovascular disease ; Clinical trials ; Exercise Therapy ; Female ; Heart ; Heart attacks ; Heart failure ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heart Failure, Systolic - etiology ; Heart Failure, Systolic - therapy ; Hospitalization ; Humans ; Illnesses ; Male ; Medical sciences ; Middle Aged ; Mortality ; Older people ; Patients ; Severity of Illness Index ; Treatment Outcome ; Ventricular Dysfunction, Left</subject><ispartof>The American heart journal, 2011-12, Vol.162 (6), p.1003-1010</ispartof><rights>Mosby, Inc.</rights><rights>2011 Mosby, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Mosby, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Dec 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</citedby><cites>FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25305181$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22137073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Whellan, David J., MD, MHS</creatorcontrib><creatorcontrib>Nigam, Anil, MD</creatorcontrib><creatorcontrib>Arnold, Malcolm, MD</creatorcontrib><creatorcontrib>Starr, Aijing Z., MS</creatorcontrib><creatorcontrib>Hill, James, MD, MS</creatorcontrib><creatorcontrib>Fletcher, Gerald, MD</creatorcontrib><creatorcontrib>Ellis, Stephen J., PhD</creatorcontrib><creatorcontrib>Cooper, Lawton, MD</creatorcontrib><creatorcontrib>Onwuanyi, Anekwe, MD</creatorcontrib><creatorcontrib>Chandler, Bleakley, MD</creatorcontrib><creatorcontrib>Keteyian, Steven J., PhD</creatorcontrib><creatorcontrib>Ewald, Greg, MD</creatorcontrib><creatorcontrib>Kao, Andrew, MD</creatorcontrib><creatorcontrib>Gheorghiade, Mihai, MD</creatorcontrib><title>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathy</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Clinical trials</subject><subject>Exercise Therapy</subject><subject>Female</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Heart Failure, Systolic - etiology</subject><subject>Heart Failure, Systolic - therapy</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Older people</subject><subject>Patients</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Ventricular Dysfunction, Left</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9ks1uEzEUhUcIREPhAdggSwjBJsE_ydgjJKQStbRSpS4Ia8uxrxOHiR1sT8TseAiei4fgSfCQlEpddGVZ_s65Pz5V9ZLgCcGkfr-ZqPVmQjEhE9xMMOGPqhHBDR_XfDp9XI0wxnQsOGYn1bOUNuVaU1E_rU4oJYxjzkbV70_gwbqMgkXwA6J2CVBeQ1S7HtkQUepTDq3TaA0qZmSVa7sIyHkUoVXZBY9yQKbIVFEm2EN0uUfKGwTltQ2r_s_PX9Z54_wqIRvDdvBHl__sLo52A36G5sHnGNoWDFpEp1p05feQsluVOn6FbrqswxbS0Ov5ba-LqJwfXlPuTP-8emJVm-DF8Tytvl6cL-aX4-ubz1fzs-uxrjHPY2saYQXDRtuGGWGYXtqpJYwsl5wLwmdKzAQwRY2iVlDGLK2N4LW2S1ETmLHT6u3BdxfD9670KLcuaWhb5SF0STZYcNbUdVPIdw-SZMamgoipGExf30M3oYu-zFEoQmssGjoYkgOlY0gpgpW76LYq9pJgOcRCbmSJhRxiIXEjSyyK5tXRuVtuwfxX3OagAG-OgEpatTYqX7Z7x80YnhFBCvfhwEFZ7t5BlEk78BqMi6CzNME92MbHe2rdls8rBb9BD-luWpmoxPLLkN8hvoRgzDGl7C-5u-6t</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Whellan, David J., MD, MHS</creator><creator>Nigam, Anil, MD</creator><creator>Arnold, Malcolm, MD</creator><creator>Starr, Aijing Z., MS</creator><creator>Hill, James, MD, MS</creator><creator>Fletcher, Gerald, MD</creator><creator>Ellis, Stephen J., PhD</creator><creator>Cooper, Lawton, MD</creator><creator>Onwuanyi, Anekwe, MD</creator><creator>Chandler, Bleakley, MD</creator><creator>Keteyian, Steven J., PhD</creator><creator>Ewald, Greg, MD</creator><creator>Kao, Andrew, MD</creator><creator>Gheorghiade, Mihai, MD</creator><general>Elsevier Inc</general><general>Mosby</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</title><author>Whellan, David J., MD, MHS ; Nigam, Anil, MD ; Arnold, Malcolm, MD ; Starr, Aijing Z., MS ; Hill, James, MD, MS ; Fletcher, Gerald, MD ; Ellis, Stephen J., PhD ; Cooper, Lawton, MD ; Onwuanyi, Anekwe, MD ; Chandler, Bleakley, MD ; Keteyian, Steven J., PhD ; Ewald, Greg, MD ; Kao, Andrew, MD ; Gheorghiade, Mihai, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathy</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Clinical trials</topic><topic>Exercise Therapy</topic><topic>Female</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Heart Failure, Systolic - etiology</topic><topic>Heart Failure, Systolic - therapy</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Older people</topic><topic>Patients</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Ventricular Dysfunction, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Whellan, David J., MD, MHS</creatorcontrib><creatorcontrib>Nigam, Anil, MD</creatorcontrib><creatorcontrib>Arnold, Malcolm, MD</creatorcontrib><creatorcontrib>Starr, Aijing Z., MS</creatorcontrib><creatorcontrib>Hill, James, MD, MS</creatorcontrib><creatorcontrib>Fletcher, Gerald, MD</creatorcontrib><creatorcontrib>Ellis, Stephen J., PhD</creatorcontrib><creatorcontrib>Cooper, Lawton, MD</creatorcontrib><creatorcontrib>Onwuanyi, Anekwe, MD</creatorcontrib><creatorcontrib>Chandler, Bleakley, MD</creatorcontrib><creatorcontrib>Keteyian, Steven J., PhD</creatorcontrib><creatorcontrib>Ewald, Greg, MD</creatorcontrib><creatorcontrib>Kao, Andrew, MD</creatorcontrib><creatorcontrib>Gheorghiade, Mihai, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Whellan, David J., MD, MHS</au><au>Nigam, Anil, MD</au><au>Arnold, Malcolm, MD</au><au>Starr, Aijing Z., MS</au><au>Hill, James, MD, MS</au><au>Fletcher, Gerald, MD</au><au>Ellis, Stephen J., PhD</au><au>Cooper, Lawton, MD</au><au>Onwuanyi, Anekwe, MD</au><au>Chandler, Bleakley, MD</au><au>Keteyian, Steven J., PhD</au><au>Ewald, Greg, MD</au><au>Kao, Andrew, MD</au><au>Gheorghiade, Mihai, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>162</volume><issue>6</issue><spage>1003</spage><epage>1010</epage><pages>1003-1010</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22137073</pmid><doi>10.1016/j.ahj.2011.09.017</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-8703 |
ispartof | The American heart journal, 2011-12, Vol.162 (6), p.1003-1010 |
issn | 0002-8703 1097-6744 |
language | eng |
recordid | cdi_proquest_miscellaneous_908739669 |
source | Elsevier |
subjects | Aged Biological and medical sciences Cardiology. Vascular system Cardiomyopathy Cardiovascular Cardiovascular disease Clinical trials Exercise Therapy Female Heart Heart attacks Heart failure Heart failure, cardiogenic pulmonary edema, cardiac enlargement Heart Failure, Systolic - etiology Heart Failure, Systolic - therapy Hospitalization Humans Illnesses Male Medical sciences Middle Aged Mortality Older people Patients Severity of Illness Index Treatment Outcome Ventricular Dysfunction, Left |
title | Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A21%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benefit%20of%20exercise%20therapy%20for%20systolic%20heart%20failure%20in%20relation%20to%20disease%20severity%20and%20etiology%E2%80%94findings%20from%20the%20Heart%20Failure%20and%20A%20Controlled%20Trial%20Investigating%20Outcomes%20of%20Exercise%20Training%20study&rft.jtitle=The%20American%20heart%20journal&rft.au=Whellan,%20David%20J.,%20MD,%20MHS&rft.date=2011-12-01&rft.volume=162&rft.issue=6&rft.spage=1003&rft.epage=1010&rft.pages=1003-1010&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2011.09.017&rft_dat=%3Cproquest_cross%3E908739669%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1512608929&rft_id=info:pmid/22137073&rfr_iscdi=true |